Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer [0.03%]
候选替代终点与晚期胆道癌总生存期的相关性分析
Florian Castet,Carles Fabregat-Franco,John Bridgewater et al.
Florian Castet et al.
Background & aims: The use of surrogate endpoints in trials including biliary tract cancers (BTC) is growing. While this may expedite drug approval and decrease costs, it may not always correlate with an overall survival ...
Bringing genetic testing into the clinical management of people with MASLD: are we there yet? [0.03%]
遗传检测在MASLD临床管理中的应用：我们准备好了吗？
Luca Valenti,Hannes Hagström
Luca Valenti
Re: Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta [0.03%]
未经治疗的慢性δ肝炎患者的差异性HBV RNA和HBcrAg模式
James Lok,Zillah Cargill,Mark Anderson et al.
James Lok et al.
Personalized survival benefit estimation from living donor liver transplantation with a novel machine learning method for confounding adjustment [0.03%]
利用新型机器学习法修正混杂因素后估计肝移植生存受益的个性化评估方法
Anirudh Gangadhar,Bima J Hasjim,Xun Zhao et al.
Anirudh Gangadhar et al.
Background & aims: Many clinical questions, such as estimating survival differences between living donor (LDLT) and deceased donor liver transplantation (DDLT), are limited to observational studies and cannot be answered ...
Challenges in Applying MASLD Risk Algorithms in Pregnancy: A Call for Adaptation and Inclusion [0.03%]
妊娠期应用MASLD风险算法的挑战：适应与包容的呼吁
Nina Rodriguez,Cecilia Katzenstein,Marcia Lange et al.
Nina Rodriguez et al.
Rethinking hepatic encephalopathy: Gut microbes, neurotoxins and the therapeutic horizon [0.03%]
重新思考肝性脑病：肠道微生物、神经毒素和治疗前景
Cornelius Engelmann
Cornelius Engelmann
Cause-specific mortality in patients with steatotic liver disease in the United States [0.03%]
美国脂肪肝患者的特异性死亡原因分析
Pedro Ochoa-Allemant,Rebecca A Hubbard,David E Kaplan et al.
Pedro Ochoa-Allemant et al.
Background & aims: Causes of death across steatotic liver disease (SLD) subtypes remain incompletely characterized in routine clinical practice. We aimed to quantify and compare cause-specific mortality in SLD. ...
Corrigendum to "CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis" [J Hepatol (2014) 61:1365-75] [0.03%]
“CXCL10 在炎症介体和非酒精性steatohepatitis的无创生物标记物方面扮演一个关键角色”[J Hepatol（2014）61：1365-75] 的勘误表
Xiang Zhang,Jiayun Shen,Kwan Man et al.
Xiang Zhang et al.
Published Erratum
Journal of hepatology. 2025 May 24:S0168-8278(25)00157-6. DOI:10.1016/j.jhep.2025.03.002 2025